Could Proxy Advisers Sway Investors to Vote ‘No’ on BMS-Celgene Merger? - Pharma News -BoardProspects

Could Proxy Advisers Sway Investors to Vote ‘No’ on BMS-Celgene Merger?

Pharma News Mar 21 2019 BoardBlogs

After Bristol-Myers Squibb and activist investor Starboard Value released dueling presentations on the planned $74 billion merger with Celgene earlier this week, Wall Street analysts started speculating about what might actually cause the deal to go south...
Read Full Article

Bookmark or Share this article

Login to comment.
Related Articles
- Shareholders Are King As Activist Cruiser Warns Boards Are Broken also categorized in BoardBlogs
- Actavis Chairman Joins Zoetis Board Under Deal With Activist Investor Ackman also published in Pharma News
- Who Would Buy Tesla And Why? also categorized in BoardBlogs
- How To Be A Valuable Board Member also categorized in BoardBlogs
- How To Write A Board Resume That Markets You As A 'Next-Gen' Voice also categorized in BoardBlogs
- Are You Ready To Serve on a Corporate Board? also categorized in BoardBlogs
- Board Of Directors And The Digital Revolution also categorized in BoardBlogs
- Crashing The Board also categorized in BoardBlogs
- How The First 15 Minutes Of Amazon’s Leadership Meetings Spark Great Ideas And Better Conversations also categorized in BoardBlogs
- AstraZeneca Director Pushing to Tie Exec Pay to Big Growth Promises also published in Pharma News

Search:
Categories
1. BoardProspects Features:
  BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Question of The Week, Sponsored Content
Topics Mentioned
- Management
- Investors
- acquisition
- Risk
- Wall Street
- ISS
- Credit Suisse
- AstraZeneca
- Starboard Value
- Bristol-Myers Squibb
- Pascal Soriot
- CEO
- Merger
- stake